Key facts
- It has raised $55.0M across 2 recorded rounds; the latest was Later Stage VC (Series D) ($55.0M) in Aug 2021.
- 3 institutional filers report fund marks on ARS Pharmaceuticals across 8 filings.
- ARS Pharmaceuticals has filed 2 Form Ds with the SEC since 2018, most recently Sep 2021 ($55.0M sold to 8 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for ARS Pharmaceuticals
Create free account
No card required
Funding rounds
2 roundsAug 2021Later Stage VC (Series D)$55.0M▮
About ARS Pharmaceuticals
- Industry
- Pharmaceuticals
PA Mark — not yet priced
ARS Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in ARS Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
3 filers · latest May 20263 SEC-registered funds reported 8 fair-value marks on ARS Pharmaceuticals between May 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.